ONC201

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Endometrial CancerDiffuse Intrinsic Pontine Glioma

85 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

1

Taxol

Teva

Phase 3

522

Keytruda

Merck & Co.

Phase 3

213

Femara

Novartis

Phase 3

174

Paraplatin

AAvyxa

Phase 3

375

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

286

Megace

Bristol-Myers Squibb

Phase 3

97

Lenvima

Eisai

Phase 3

68

Lynparza

AstraZeneca

Phase 3

69

Tecentriq

Roche

Phase 3

410

Trodelvy

Gilead

Phase 3

3Show 47 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma3 trials

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

No longer available·Jazz Pharmaceuticals··NCT05392374

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05476939·433 enrolled

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05009992·360 enrolled

Endometrial Cancer2 trials

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05542407·58 enrolled

A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Terminated·FFox Chase Cancer Center·Phase 2·NCT03099499·19 enrolled

Multiple Myeloma2 trials

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated·AAjai Chari·Phase 1/2·NCT03492138·5 enrolled

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Terminated·Jazz Pharmaceuticals·Phase 1/2·NCT02863991·17 enrolled

Patients With Advanced Solid Tumors2 trials

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Completed·RRutgers, The State University of New Jersey·Phase 1·NCT02324621·26 enrolled

Oral ONC201 in Treating Patients With Advanced Solid Tumors

Completed·RRutgers, The State University of New Jersey·Phase 1·NCT02250781·58 enrolled

Glioma2 trials

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Approved for marketing·Jazz Pharmaceuticals··NCT04617002

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

No longer available·Jazz Pharmaceuticals··NCT03134131

5 more indications

Advanced Cancer1 trial

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Withdrawn·Jazz Pharmaceuticals·Phase 1/2·NCT02038699

Endometrial Carcinoma1 trial

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03394027·30 enrolled

Meningioma1 trial

A Study of ONC201 for Refractory Meningioma

Withdrawn·UUniversity of Nebraska·Phase 2·NCT06012929

Neuroendocrine Tumors1 trial

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Completed·PPeter Anderson·Phase 2·NCT03034200·30 enrolled

Glioblastoma1 trial

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04629209

Details

Drug Info

Related News